Too much of a hormone commonly used during in vitro fertility treatments actually decreases a woman’s chances of having a baby, report researchers.
The research, recently published in the journal Fertility and Sterility, is the largest study to analyze more than 650,000 IVF cycles in women in the United States.
James Ireland, professor in reproductive physiology at Michigan State University and one of the coauthors of the study, concludes that as the total dose of the hormone known as follicle stimulating hormone, or FSH, went up, the live birth rate went down.
This finding supports other smaller studies and reverses the traditional thought that the more FSH given during treatment, the better probability of a woman conceiving.
FSH is produced by the pituitary gland. The hormone controls the ovaries in women and testes in men and is essential for reproduction. Doctors use FSH to stimulate as many follicles as possible in a woman’s ovaries to grow, so a large number of eggs can be recovered for IVF.
“The study answers the question of whether or not more FSH is detrimental to the survival of the embryo,” Ireland says. “As the dosage of FSH increased, live birth rates decreased by as much as 15 to 20 percent.”
In addition, the research team found that this decline still occurred regardless of age, health, weight of the patient, or length of treatment.
“Our driving force for this research was not only to investigate whether high doses of FSH could impact embryo survival, but to also develop markers in future studies for clinicians to use and determine when an FSH dosage becomes too much,” Ireland says. “Ultimately, they may want to know how to avoid higher amounts of the hormone.”
Baker, Valerie L. et al. Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles Fertility and Sterility , Volume 104 , Issue 5 , 1145 - 1152.e5